Abbott has grown its earnings per share at a nearly 10% compound annual rate over the past decade. I

Oncology stocks are gaining relevance as cancer care evolves, with Pfizer, Merit Medical Systems and

These companies might bend during a downturn, but they won't break.

The recommendations of Wall Street analysts are often relied on by investors when deciding whether t

Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile

Analysts initiated coverage: Overweight GNRC ($303), Buy ENTG ($200) and VYLR ($87), Neutral SPOT ($

Analysts raised targets for Everpure, Eli Lilly and Delek US, while cutting targets for Constellatio

New powder combines 30 grams of high‑quality protein to help build muscle tissue,† 5 grams of creati

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys

Analysts initiated coverage: Neutral on Honeywell Aerospace; Outperform on M&T Bank and SailPoin

Wall Street analysts revised targets: upgrades for NetApp and Humana; downgrades for PJT Partners; m

Barclays analyst Matt Miksic initiates coverage on Abbott Laboratories (NYSE:ABT) with a Overweig

Stocks shattered records again Tuesday while oil surged, gold hit new highs, and crypto swung wildly

Abbott (ABT) closed the most recent trading day at $98.16, moving 1.94% from the previous trading se

Both Medtronic and Abbott have dropped in 2026, and those declines reshuffled the math on yield, val

Wall Street analysts raised targets for PTC, Cloudflare, PENN, Microsoft and others, while downgradi

Park National Corp OH lessened its position in shares of Abbott Laboratories (NYSE: ABT) by 6.8% in

Eastern Bank trimmed its position in Abbott Laboratories (NYSE: ABT) by 14.1% in the third quarter,

Abbott (NYSE: ABT), the global healthcare leader, today announced U.S. Food and Drug Administration

For the first time, U.S. CardioMEMS patients will be able to view pulmonary artery pressure (PAP) re

Analysts raised targets for ON, AMD and WTFC, while cutting GNRC, LAD, ALGN, PLNT and CRDO; ALGN was

Analysts raised targets for ACN, SYNA, ATRC and MPC; cut targets for CSX, NKE, MKC and FHTX, with AT

Analysts upgraded HPE, Abbott, Airbnb, Horizon Bancorp and Triumph Financial, raising or setting pri

Rothschild & Co analyst Ed Ridley-Day upgrades Abbott Laboratories (NYSE:ABT) from Neutral to

Records from September 22, 2026 indicate that Representative Rick Allen of Georgia made a sale of Ro

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

TD Cowen analyst Joshua Jennings reiterates Abbott Laboratories (NYSE:ABT) with a Buy and maintai

Abbott's TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ combines pulsed field ablation (PFA)

The FDA authorized Abbott's Libre Duo 10 Day, the first wearable tracking both glucose and keton

The U.S. Food and Drug Administration today authorized the Libre Duo 10 Day Continuous Dual Glucose

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Abbott agreed to pay $670 million to resolve the Gill lawsuit and 2,000 other NEC claims involving i

Abbott (NYSE: ABT) has reached agreements with three law firms to resolve the Gill case and claims i

HealthTab™ provides a complete, turnkey solution underpinning national pharmacy-based PoCT networks,

An official report on August 18, 2026 reveals Representative Rick Allen's recent sale of Abbott

Records from August 14, 2026 indicate that Representative Richard Dean Dr McCormick of Georgia made

A congressman reported selling stocks recently, while also investing in a municipal bond.

Wolfe Research analyst Mike Polark upgrades Abbott Laboratories (NYSE:ABT) from Peer Perform to O

The collaboration is designed to bring metabolic health insights into people's daily routines th

UBS analyst Patrick Wood maintains Abbott Laboratories (NYSE:ABT) with a Buy and lowers the price

Screening is for colorectal cancer (CRC) in adults 45 and older who are at average risk for the dise

Citigroup analyst Joanne Wuensch maintains Abbott Laboratories (NYSE:ABT) with a Buy and raises t

Piper Sandler analyst Adam Maeder reiterates Abbott Laboratories (NYSE:ABT) with a Overweight and

JP Morgan analyst Robbie Marcus maintains Abbott Laboratories (NYSE:ABT) with a Overweight and ra

Wells Fargo analyst Larry Biegelsen maintains Abbott Laboratories (NYSE:ABT) with a Overweight an

TD Cowen analyst Joshua Jennings reiterates Abbott Laboratories (NYSE:ABT) with a Buy and maintai

Abbott Laboratories (NYSE:ABT) reported strong Q2 results, raising its full-year earnings outlook. A

Evercore ISI Group analyst Vijay Kumar maintains Abbott Laboratories (NYSE:ABT) with a Outperform

RBC Capital analyst Shagun Singh reiterates Abbott Laboratories (NYSE:ABT) with a Outperform and

Recent analyst rating changes, top names such as PPG, SAH, ISRG, MMM, OKE, GLDG, ABT, NFLX, TSCO, an